Company Overview - Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis [1][4] - The company's mission is to provide patients with significant freedom from chronic skin conditions by achieving high rates of complete disease clearance with infrequent dosing, potentially as little as once or twice a year [4] Leadership Change - Laura Sandler has been promoted to Chief Operating Officer, having previously served as Senior Vice President of Operations since 2024 [1][2] - Ms. Sandler brings over 20 years of biopharmaceutical leadership experience, particularly in clinical operations and development strategy, and has been instrumental in advancing Oruka's programs into clinical trials [2][3] Strategic Focus - The company is advancing a proprietary portfolio of potentially best-in-class antibodies targeting the core mechanisms of plaque psoriasis and other dermatologic and inflammatory diseases [4] - Ms. Sandler expressed commitment to driving the company's programs forward with urgency, rigor, and high quality, aligning with the expectations of patients and investors [4][3]
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer